Login to Your Account

Bluebird feathers nest with $95M; stock sale to push gene therapy

By Randy Osborne
Staff Writer

Thursday, July 10, 2014
Riding high on the gene therapy wave, Bluebird Bio Inc. will more than replace its spend on last month's acquisition of Pregenen Inc. by way of selling 3 million shares of stock at $34 each for net proceeds of about $95.6 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription